ACTUATE THERAPEUTICS, INC.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- ACTUActuate Therapeutics Inc.0Calm
Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors
Not started yetPhase 1/2100 patientsMain results: Jul 2029 - ACTUActuate Therapeutics Inc.0Calm
9-ING-41 in Patients With Advanced Cancers
Running, no new patientsPhase 2350 patientsMain results: Jun 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 1 purchase
- SCHMITT DANIEL MPresident, CEO and Director · Oct 28, 2026Bought 140,844 sharesabout $50 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Warning about being removed from the stock exchangeNews report (8-K)Oct 30, 2026
- Signed a major agreement; Other newsNews report (8-K)Oct 28, 2026
- New shares being soldNew shares being sold (424B5)Oct 28, 2026
- Permission to sell new sharesPermission to sell new shares (S-1)Oct 6, 2026
- Quarterly reportQuarterly report (10-Q)Aug 14, 2026
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.